Futures are pointing to a rebound at the Friday Wall Street open ahead of the long holiday weekend, but not nearly enough to make up for the week's losses.Morning Briefread more
May had failed to win a parliamentary majority on Britain's withdrawal from the European Union.Europe Politicsread more
"We have a high degree of confidence that AMZN shares can reach this level with no major acquisitions or other significant changes to the business."Investingread more
Investors are rushing into the relative safe haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
China denounced U.S. Secretary of State Mike Pompeo for fabricating rumors after he said the chief executive of China's Huawei was lying about his company's ties to the...World Politicsread more
U.S. President Donald Trump on Thursday predicted a swift end to the ongoing trade war with China, although no high-level talks have been scheduled between the two countries.World Economyread more
A downgrade from BMO analysts led to an unsavory drop in Chipotle's stock, and some analysts are advising waiting out the weakness.Trading Nationread more
President Donald Trump has threatened tariffs on another $300 billion worth of Chinese goods — but Chinese PC-maker Lenovo is prepared to shift its production if that happens,...Technologyread more
Indian Prime Minister Narendra Modi won a landslide re-election victory. That could see India taking a more assertive security stance.Asia Politicsread more
The Wall Street Journal and The New York Times, citing people familiar with the deal, reported that $30 million would go to plaintiffs and $14 million would be used to pay...Entertainmentread more
Danish shipping group A.P. Moller-Maersk on Friday posted first-quarter profit close to expectations and warned that trade tensions and slowing economic growth constitute...Earningsread more
won big and early this new year.
Its FreeStyle Libre continuous glucose monitor received Medicare coverage, one month after it was launched, the company said Thursday. The decision comes and between 9 and 12 months ahead of Wall Street's expectations, J.P. Morgan analyst Michael Weinstein wrote in a note following the announcement.
The product is the first continuous glucose monitor on the market that doesn't require patients to prick their finger to draw blood. from FreeStyle Libre even before Thursday's announcement because the company is aggressively pricing and marketing the new technology.
Yet they saw limits from patients having to pay for it out-of-pocket while Abbott waited for coverage approval from insurance companies and the Centers for Medicare & Medicaid Services. CMS oversees federal health programs such as Medicare and Medicaid.
J.P. Morgan on Tuesday had estimated FreeStyle Libre to generate $68 million in sales in 2018, with upside up to about $100 million if Abbott secured either commercial reimbursement, Medicare reimbursement, or labeling for kids earlier than expected.
The announcement pits Abbott against rival in the battle for Medicare patients. Dexcom's G5 system requires calibration, while Abbott's does not. that doesn't require fingerstick testing by the end of the year.
Medicare patients will choose between Abbott's FreeStyle Libre and Dexcom's G5 based on features and ease of use because the cost is the same, Weinstein wrote. Dexcom's device has Bluetooth connectivity, but the feature isn't available for Medicare patients.
"So for elderly Medicare patients, the choice is the very easy to use non-continuous Libre, or the somewhat more complicated G5, but without the online features," Weinstein wrote. "As the price to the patient is the same, the easy to use option will certainly be appealing to an elderly population."
Shares of Abbott fell 0.2 percent on Thursday, while shares of Dexcom fell about 10 percent.